

CLAIMS

1. Use of a first antiviral agent in the preparation of a medicament for pre-exposure prophylaxis against HSV infection in an HSV seronegative subject, in which the treatment comprises orally administering to the subject a therapeutically effective amount of the first
5 antiviral agent.
2. Use according to Claim 1, in which the method further comprises administering to a HSV seropositive partner a therapeutically effective amount of a second antiviral agent.
3. Use according to Claim 1 or 2, in which the administering comprises delivering the first antiviral agent to the subject in a sustained-release form.
- 10 4. Use according to Claim 1, 2 or 3, in which the first antiviral agent comprises valacyclovir, acyclovir, famciclovir, pritelivir, tenofovir, ganciclovir, glycyrrhizic acid, sambucus nigra, valganciclovir, or a salt, solvate or combination thereof.
5. Use according to any preceding claim, in which the method further comprises administering to the subject a therapeutically effective amount of an additional antiviral agent.
- 15 6. Use according to any preceding claim, in which the method further comprises administering to the subject an effective amount of a contraceptive.
7. Use of a first antiviral agent in the preparation of a medicament for pre-exposure prophylaxis against HSV infection in an HSV seronegative subject, in which the treatment comprises orally administering to the subject a therapeutically effective amount of the first
20 antiviral agent after physical contact with a partner who is seropositive for HSV.
8. Use according to Claim 7, in which the method further comprises administering to the subject a therapeutically effective amount of an additional antiviral agent.
9. Use according to Claim 7 or 8, in which the method further comprises administering to a HSV seropositive partner a therapeutically effective amount of a second antiviral agent.
- 25 10. Use according to Claim 7, 8 or 9, in which the administering comprises delivering the first antiviral agent to the subject in a sustained-release form.
11. Use according to any of Claims 7 to 10, in which the first antiviral agent comprises valacyclovir, acyclovir, famciclovir, pritelivir, tenofovir, ganciclovir, glycyrrhizic acid, sambucus nigra, valganciclovir, or a salt, solvate or combination thereof.
- 30 12. Use according to any of Claims 7 to 11, in which the method further comprises administering to the subject a therapeutically effective amount of an HIV antiviral agent.
13. Use according to any of Claims 7 to 12, in which the method further comprises administering to the subject an effective amount of a contraceptive.

14. Use according to Claim 13, in which the contraceptive is an emergency contraceptive.

15. An HSV treatment kit comprising:

(a) a therapeutically effective amount of a first antiviral agent;

(b) a delivery device for orally delivering the first antiviral agent to an HSV
5 seronegative subject; and

(c) instructions comprising information on how to administer the first antiviral agent
using the delivery device to prevent HSV infection in the HSV seronegative subject.

16. A kit according to Claim 15, in which the therapeutically effective amount of the first
antiviral agent is:

10 (a) an amount useful for the prevention of HSV infection in the HSV seronegative
subject when administered to the HSV seronegative subject prior to exposure to HSV;

(b) an amount useful for suppression of HSV in a seropositive subject; provided that
the delivery device further provides a method for delivering the first antiviral agent to
the HSV seropositive subject; and provided that the instructions further comprise
15 information on how to administer the first antiviral agent using the delivery device to
suppress HSV reactivation in the HSV seropositive subject;

(c) an amount useful for the prevention of HSV infection in the HSV seronegative
subject when administered after the HSV seronegative subject is exposed to HSV;

(d) an amount useful for treatment of an outbreak of HSV in a seropositive subject;
20 provided that the delivery device further provides a method for delivering the first
antiviral agent to the HSV seropositive subject; and provided that the instructions further
comprise information on how to administer the first antiviral agent using the delivery
device to treat an HSV outbreak in the HSV seropositive subject; or

(e) an amount useful for any combination of the indications of (a) to (d).

25 17. A kit according to Claim 15 or 16, in which the delivery device is in a sustained-release
form.

18. A kit according to Claim 15, 16 or 17, further comprising an effective dose of a
contraceptive.

19. Use according to any of Claims 1 to 14 or a kit according to any of Claims 15 to 18, in
30 which the HSV is a cytomegalovirus or an Epstein-Barr virus.

20. Use of a combination of a first antiviral agent and an HIV antiviral agent in the preparation of a medicament for pre-exposure prophylaxis against HIV and HSV infection in an HSV seronegative subject, in which the method comprises the method comprising orally administering to the subject a therapeutically effective amount of the first antiviral agent and a
5 therapeutically effective amount of the HIV antiviral agent after physical contact with a partner who is seropositive for HIV and/or HSV.
21. Use according to Claim 20, in which the HSV seronegative subject is seronegative for HIV.
22. Use according to Claim 20, in which the HSV seronegative subject is seropositive for
10 HIV.
23. Use according to any of Claims 1 to 14 and 19, a kit according to any of Claims 15 to 19 or a use according to Claim 20, 21 or 22, in which the first antiviral agent comprises famciclovir and valacyclovir.
24. Use according to any of Claims 1 to 14, 19 and 23, a kit according to any of Claims 15
15 to 19 and 23 or a use according to any of Claims 20 to 23, in which the therapeutically effective amount further comprises an adjuvant.